CD274 and non-small cell lung carcinoma: Based on the FDA approvement, nivolumab and pembrolizumab (anti-PD-1 antibody) and atezolizumab (an anti-PD-L1 antibody) are granted as the second-line treatment of advanced NSCLC on the basis of improvements in OS versus docetaxel [9–11].